Pharma Journalist -

Merck known as MSD outside of the United States and Canada, announced that KEYTRUDA, Merck’s anti-PD-1 therapy, received four new approvals from Japan’s Ministry of Health, Labor and…
Read More...

Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Design platform for genetic medicine, announced a strategic collaboration with Sanofi for the use of…
Read More...

Sciwind Biosciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease and SynerK, a leading RNAi…
Read More...

Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular diseases, announced the dosing with ATA-100 of a first…
Read More...

Pulse Biosciences, Inc. a novel bioelectric medicine company developing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, announced receipt of U.S. Food and Drug…
Read More...

Pfizer Inc. and BioNTech SE announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster…
Read More...

Seagen Inc. and LAVA Therapeutics N.V. announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an advanced…
Read More...

Emergent BioSolutions Inc. announced that it has completed its acquisition of exclusive worldwide rights to TEMBEXA (brincidofovir), the first oral antiviral approved by the U.S. Food…
Read More...

SAE Media Group reports: Conference co-chairs invite you to attend the 2nd Annual Next Generation Pharmaceutical Cleanrooms this October 2022. The conference will be co-chaired…
Read More...

AstraZeneca and MSD’s Lynparza (olaparib) has been approved in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary…
Read More...